Novartis (SWX: NOVN) reported earnings on Jan. 25. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Novartis met expectations on revenue and missed on earnings per share.

Compared to the prior-year quarter, revenue improved, and earnings per share dropped significantly.

Margins dropped across the board.

Revenue details
Novartis reported revenue of $14.78 billion. The 12 analysts polled by S&P Capital IQ wanted to see a top line of $14.76 billion. Sales were 3.7% higher than the prior-year quarter's $14.20 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
Non-GAAP EPS came in at $1.23. The six earnings estimates compiled by S&P Capital IQ predicted $1.26 per share on the same basis. GAAP EPS of $0.48 for Q4 were 49% lower than the prior-year quarter's $0.94 per share.

Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 65.9%, 550 basis points worse than the prior-year quarter. Operating margin was 8.8%, 1,080 basis points worse than the prior-year quarter. Net margin was 7.8%, 720 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $14.36 billion. On the bottom line, the average EPS estimate is $1.37.

Next year's average estimate for revenue is $59.54 billion. The average EPS estimate is $5.63.

Investor sentiment
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Novartis is outperform, with an average price target of $67.20.

The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Novartis the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.